ADMA Biologics's 15min chart shows MACD Death Cross, KDJ Death Cross signals.

ADMA Biologics' 15-minute chart has exhibited a MACD Death Cross and KDJ Death Cross at 10/07/2025 15:30, indicating that the stock price has the potential to continue falling. This suggests a shift in momentum towards the downside, with a potential further decrease in stock price.

Adma Biologics (ADMA) has experienced a significant downturn in its stock price following the appearance of MACD and KDJ Death Crosses on its 15-minute chart as of October 7, 2025, at 15:30. This technical indicator suggests a potential shift in momentum towards the downside, indicating a possible further decrease in the stock price.

The company's stock closed at $15.05 in the latest trading session, marking a 2.66% increase from the previous day. However, this gain was more than the S&P 500's daily gain of 0.34%, indicating a relatively stronger performance compared to the broader market. Over the past month, ADMA's stock has dropped by 14.77%, underperforming the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%.

Analysts and investors are closely monitoring Adma Biologics' upcoming earnings disclosure. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the same quarter last year. The consensus estimate for revenue is $130.1 million, a 8.56% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, representing changes of +16.33% and +18.82%, respectively, from the preceding year Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Despite these positive earnings projections, the stock's recent performance and the appearance of the MACD and KDJ Death Crosses warrant caution. The Zacks Rank for ADMA is currently #3 (Hold), indicating a neutral outlook. The company is trading at a Forward P/E ratio of 25.72, which is a premium compared to the industry average of 18.92. The Medical - Biomedical and Genetics industry, which ADMA is part of, is ranked #80 by Zacks, placing it in the top 33% of all 250+ industries Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

Investors should be aware of any recent modifications to analyst estimates for ADMA, as these revisions can provide insights into the changing nature of near-term business trends. Positive revisions in estimates can indicate analysts' confidence in the company's performance and profit potential Why Adma Biologics (ADMA) Outpaced the Stock Market Today^[1].

In conclusion, while Adma Biologics' earnings projections are promising, the recent technical indicators suggest a potential downward trend in the stock price. Investors should closely monitor the company's performance and the evolving market conditions.